Evaluation of Buspirone on Streptozotocin Induced Type 1 Diabetes and Its Associated Complications

Abstract

We have evaluated the effect of buspirone (1.5 mg/kg/day, p.o.) type 1 diabetes induced cardiovascular complications induced by streptozotocin (STZ, 45 mg/kg, i.v.) in Wistar rats. Various biochemical, cardiovascular, and hemodynamic parameters were measured at the end of 8 weeks of treatment. STZ produced significant hyperglycaemia, hypoinsulinemia, and dyslipidemia, which was prevented by buspirone treatment. STZ produced increase in serum creatinine, urea, lactate dehydrogenase, creatinine kinase, and C-reactive protein levels and treatment with buspirone produced reduction in these levels. STZ produced increase in cardiac and LV hypertrophy index, LV/RV ratio, and LV collagen, which were decreased by buspirone treatment. Buspirone also prevented STZ induced hemodynamic alterations and oxidative stress. These results were further supported by histopathological studies in which buspirone showed marked reduction in fibrosis and cardiac fiber disarray. In conclusion, our data suggests that buspirone is beneficial as an antidiabetic agent in type 1 diabetes mellitus and also prevents its cardiac complications.

Garlic Attenuates Plasma and Kidney ACE‐1 and AngII Modulations in Early Streptozotocin‐Induced Diabetic Rats: Renal Clearance and Blood Pressure Implications

“…On one hand, a group of studies have reported no change [ 55 ] or even a decrease [ 56 , 57 ] in the exhibited BP. Alternatively, more recent studies, in agreement with the current observation, reported hypertension in the majority [ 58 – 60 ] or a good percentage of the diabetic rats [ 61 ]. This view is even supported by the findings of a human study on the same type of diabetes [ 62 ].…”

Wistar rats with long-term streptozotocin-induced type 1 diabetes mellitus replicate the most relevant clinical, biochemical, and hematologic features of human diabetes / Sobolanii Wistar cu diabet zaharat tip 1 indus cu streptozotocina reproduc cele mai relevante caracteristici clinice, biochimice si hematologice ale diabetului uman

“…Blood pressure and heart rate changes in diabetic rats Blood pressure and heart rate analysis demonstrated that although there was no significant difference in systolic blood pressure between non-diabetic and diabetic rats, the latter were significantly more bradycardic, as already reported in previous studies (18). However, our study demonstrates that the lower heart rates seen in diabetics were not due to an actual bradycardization of these rats, in which the heart rates were not significantly different than those recorded prior to STZ administration, but rather to a lack of increase in heart rate as that seen in controls.…”

“…The significant dyslipidemia observed in these rats may play a significant role in this regard, although the presence of mediocalcinosis, commonly seen in diabetic patients, cannot be excluded. Indeed, whilst studies using non-invasive blood pressure measurement consistently reported no changes in blood pressure in diabetic rats, invasive measurement by arterial catheterization seems to confirm the presence of arterial hypertension (18). Since invasive blood pressure measurement was not performed in the present study, this hypothesis remains to be confirmed.…”

Resveratrol protects against early cardiomyopathic changes-induced by Type-1 diabetes through a heme-oxygenase-1 dependent mechanism

“…In the present study, induction of diabetes did not cause apparent cardiomegaly. This was excepted as previous studies showed that the increase in heart weight and associated change in cardiac parameters could be only observed after 8-weeks of induction of diabetes in rats [30,31]. However, histopathological examination revealed the presence of inflammatory cells infiltration, numerous focal haemorrhages, sclerosis and narrowing in the myocardial blood vessels.…”